Frazier Healthcare Partners has launched Recida Therapeutics, a biopharmaceutical company focused on the development of novel therapeutics for serious antibiotic-resistant infections.
GlaxoSmithKline (GSK) and Merck will develop and commercialize novel immunotherapy to treat multiple cancers, under €3.7bn worth deal.
Frontier IP, a specialist in commercialising university intellectual property, today announces portfolio company Amprologix (the "Company") has won a contract worth £1.2 million funded by the UK Department for Health and Social Care to accelerate development and scale up its lead antibiotic candidate to tackle antimicrobial resistant MRSA and related superbugs.
IQVIA has announced the launch of IQVIA Biotech and its new approach to delivering tailored clinical and commercial solutions for small biotech and biopharma companies.
Fortress Biotech, a biopharmaceutical company focused on acquiring, developing and commercializing pharmaceutical and biotechnology products, announced that Caelum Biosciences has signed a strategic agreement with Alexion Pharmaceuticals to advance the development of CAEL-101 for light chain (AL) amyloidosis.
Janssen Pharmaceuticals and MeiraGTx have signed an agreement worth $440m to develop gene therapy programs for inherited retinal diseases (IRDs).
Dewpoint Therapeutics, a company translating the emerging area of biomolecular condensates into drug discovery, launched today with a $60 million Series A.
Lyndra Therapeutics, which is moving toward making daily pills a thing of the past, has raised $55 million in Series B financing, funds it will use for Phase II clinical trials, expansion of its Phase I pipeline and manufacturing scale-up.
Finnish pharmaceutical firm Orion Oyj has signed a loan agreement of €100m with the European Investment Bank in Espoo.
BridgeBio Pharma, a clinical-stage biopharmaceutical firm focused on the development of medicines for genetic diseases, has secured $299.2m funds to advanced its existing drug research and development programs.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.